8th Sep 2026 14:29
(Alliance News) - Genflow Biosciences PLC on Tuesday said results from a clinical trial showed its anti-ageing gene therapy reduced the biological age of elderly dogs.
The London-based biotechnology company specialising in treatments for age-related diseases said its trial in aged beagles met its main target, with treated animals showing an improvement compared with those that did not receive the treatment.
The randomised, blinded trial enrolled 24 beagles aged over 10 years. They were divided into four groups. Two groups received different doses of Genflow's SIRT6 gene therapy as naked DNA, while a third received the same gene therapy delivered using AAV8, a virus used to carry genetic material into cells. The fourth group received a saline solution instead of the treatment and served as a control.
Researchers measured the beagles' biological age using the GRIM methylation clock, which analyses DNA methylation changes associated with ageing to estimate biological age.
Genflow said the results support the potential of its SIRT6 gene therapy to treat age-related decline in companion animals.
The company said it is in talks with major animal health companies about licensing the treatment or working together to develop and commercialise it.
Genflow said the results build on preliminary muscle data reported in February.
The company said it saw improvements across several other measures of the dogs' health and function. It will present detailed results from the trial at the Animal Longevity Summit in Toronto in October.
Eric Leire, chief executive officer of Genflow Biosciences, said: "Meeting the primary endpoint in SLAB is a defining milestone for Genflow. We set out to demonstrate that our centenarian SIRT6 naked DNA therapy could measurably address age-related decline in a real-world aging mode. This provides a powerful foundation for our partner discussions across animal health. We look forward to sharing the full dataset, including the critical methylation clock and muscle histology results, with the scientific and investment communities at the Animal Longevity Summit in October."
Shares in Genflow Biosciences were up 1.6% at 2.50 pence per share on Tuesday afternoon in London.
By Niall Holden, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Genflow Biosci